Compare GoPro Inc (GPRO) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GoPro Inc vs Natera Inc. Common Stock — how do they compare? GoPro Inc trades at $1.08 (market cap $243.50M), while Natera Inc. Common Stock trades at $394 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 234.2× GoPro Inc's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, GoPro Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold GoPro Inc for 45 Days and Natera Inc. Common Stock for 0 Days on average.
| GPRO | NTRA | |
|---|---|---|
Market Cap | $243.50M | $57.03B |
Volume | 7,074,005 | 1,131,157 |
Sector | Technology | Health |
52-Week High | $2.31 | $425.64 |
52-Week Low | $0.58 | $179.42 |
Typical Hold Time | 45 Days | 0 Days |
Enterprise Value | $302.28M | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GoPro trades at $1.16, down 2.52% today, as the stock consolidates after a volatile surge driven by merger news and influencer investment. The company faces fundamental challenges with negative profit margins and cash flow, though valuation ratios appear attractive with P/E of 4.56 and P/S of 0.34. Recent developments include a $285 million merger agreement with Starman Optical and YouTube creator Markiplier taking an 8.5% stake, driving significant price volatility.
The merger with Starman Optical offers strategic repositioning into AI data centers and defense markets, but shareholder lawsuits question the $1.14 per share valuation. While technical indicators show bullish momentum, fundamental weaknesses and competitive pressures from smartphones create significant investment risk. Analyst consensus remains cautious with only 21% buy ratings.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About GoPro Inc
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts, drones and appliances. The company outsources a part of manufacturing to third parties in China. The company sells products across the world through its direct sales channel, which generates over half of total revenue, and indirectly through its distribution channel. The company has presence, including in the Americas, Europe, Middle East, Africa, and Asia-Pacific, with the Americas contributing over half of total revenue.
Read more on GPRO →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
